WASHINGTON--The Food and Drug Administration approved Monday a
new lung drug designed to treat chronic obstructive pulmonary
disease that will be marketed by Forest Laboratories Inc.
(FRX).
The drug, Tudorza Pressair, is a long-acting medicine that is
delivered through an inhaler that helps muscles around the large
airways of the lungs stay relaxed to improve airflow.
Forest licensed the U.S. rights for the product from Almirall
SA. (ALM.MC) The approval was expected after an FDA advisory panel
voted to support the product at a February meeting.
Chronic obstructive pulmonary disease, marked by damaged lungs,
is the fourth-leading cause of death in the U.S., according to the
National Institutes of Health. The disease, which is primarily
caused by smoking, causes the lungs' airways to become partly
obstructed, making it difficult to breathe.
The FDA said three clinical studies of the Tudorza Pressair
showed it was effective at increasing airflow through the lungs
compared to patients receiving a placebo, or inactive drug. FDA's
safety review of the product focused on cardiovascular risks
because of concerns previously raised about the other long-acting
drug in same class of medicines used to treat COPD, Spiriva,
co-marketed by Boehringer Ingelheim GMBH and Pfizer Inc., (PFE). In
2008 the FDA started a safety review of Spiriva after receiving
information from clinical studies that suggested the medicine might
be associated with a higher stroke risk, but in 2010 the FDA
cleared Spiriva of increasing stroke or heart problems.
The FDA said Tudorza Pressair could cause serious side effects,
including narrowing of the airways, increased pressure in the eyes
or urinary retention. The agency said Tudorza Pressair should not
be used as a short-term medication to treat an acute breathing
problem and isn't recommended for people younger than 18 years
old.
Write to Jennifer Corbett Dooren at
jennifer.corbett@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires